Gastric bypass procedures, particularly Roux-en-Y gastric bypass (RYGB), fundamentally alter the stomach size and the route food takes through the digestive system
Weight loss via GLP-1s like Ozempic ($17.45B in 2024 sales, up 25% YoY) proved even more lucrative than erectile dysfunction, with Ro's GLP-1 sales 3x'ing between January 2023 and August 2024, pushing topline growth to 66% in 2024 (vs 14% in 2023 and 5% in 2022) and lifting average transaction value from ~$93 to ~$134, while Hims & Hers hit 100K GLP-1 members and ~$343M in annualized GLP-1 revenue by the end of 2024
Unfortunately, there are no clinical trials beyond 16 weeks of sermorelin therapy, and the data do not show any significant fat loss within this timeframe [5]
Juan Francisco Merino-Torres: provided expert clinical opinion and critical revision of the manuscript for important intellectual content
10.1016/j.fertnstert.2015.05.023 17 BentingerM.DallnerG.ChoknackiT.SwiezewskaE
Be safe everyone and God bless us all.
